secwatch.observer — SEC 8-K summary
======================================

Issuer:     VBI Vaccines Inc/BC (—)
CIK:        0000764195
Form:       8-K
Filed at:   2024-05-15T23:59:59+00:00
Accession:  0001493152-24-019881
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 1.02, 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

VBI Vaccines Q1 net loss $17.9M, revenue up; new $8.5M ATM, Brii Bio deal pending
--------------------------------------------------------------------------------

- Net loss $17.9M ($0.73/share) vs $27.8M ($3.22) in Q1 2023; revenue $1.2M, up from $0.5M.
- PreHevbrio global net revenue $1.0M, up 105% YoY; over 80% of 2023 full-year volume sold in first 5 months of 2024.
- Entered new $8.47M ATM with H.C. Wainwright; terminated prior $125M Jefferies ATM effective May 10.
- Cash $12.6M at March 31 (down from $23.7M); subsequent ~$2.8M from offerings through early April.
- Brii Bio deal: up to $33M consideration (milestones); expects debt to reduce to ~$17M by mid-2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/764195/000149315224019881/0001493152-24-019881-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/764195/000149315224019881/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-019881

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer